Free Trial

Eliem Therapeutics Q2 2024 Earnings Report

Eliem Therapeutics logo
$2.34 -0.08 (-3.31%)
(As of 12/17/2024 ET)

Eliem Therapeutics EPS Results

Actual EPS
-$1.81
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eliem Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eliem Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

This drone stock is setting up to transform medical supply delivery (Ad)

Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.

Click here to see how a new partnership could catapult this drone suppliers' growth

Eliem Therapeutics Earnings Headlines

This drone stock is setting up to transform medical supply delivery
Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.
See More Eliem Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eliem Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eliem Therapeutics and other key companies, straight to your email.

About Eliem Therapeutics

Eliem Therapeutics (NASDAQ:ELYM), a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

View Eliem Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings